肾细胞癌下腔静脉癌栓切除术前新辅助立体定向消融放疗的2期非随机临床试验
这项单中心前瞻性2期非随机试验评估了肾细胞癌合并Mayo II–IV级下腔静脉癌栓患者在接受肾切除术和癌栓切除术前进行新辅助立体定向消融放疗(SABR)的可行性、安全性和临床结局。23例患者接受SABR,22例完成手术,21例纳入主要分析;1年无复发生存率为71.4%(95%CI 47.2–86.0),达到预设的2期筛选标准(对比历史单纯手术基准55.7%,P=.09),安全性可接受,但结果仍属探索性。
要点
- 新辅助SABR后1年RFS为71.4%,达到预设2期筛选标准但P=.09,仍属探索性。
- 90天围手术期无死亡,无4/5级放疗相关毒性,4例出现4级治疗相关事件。
- 照射癌栓Ki-67表达较未照射对照下降,肿瘤信息循环肿瘤DNA治疗后下降。
核心结论
- 新辅助SABR后行肾切除及下腔静脉癌栓切除在这一高危人群中可行且安全性可接受。
- 1年RFS达到预设2期筛选标准,但结果仍为探索性,需要进一步评估。
研究设计与样本
- 单中心前瞻性2期非随机临床试验,2015年7月至2024年1月入组新诊断RCC伴Mayo II–IV级下腔静脉癌栓患者。
- 23例接受新辅助SABR,22例完成手术,21例纳入主要RFS分析;中位(IQR)年龄62.5(54.0–73.2)岁,12例(57%)为男性。
- SABR方案为40 Gy分5次或36 Gy分3次,随后行根治性肾切除及下腔静脉癌栓切除。
主要发现
- 中位(范围)随访108.6(2.0–127.2)个月,1年RFS为71.4%(80%CI 56.6–82.0;95%CI 47.2–86.0)。
- 与历史单纯手术基准55.7%比较,达到预设2期筛选标准(P=.09)。
- 1年总生存率为95.2%(80%CI 83.9–98.7;95%CI 70.7–99.3),癌症特异性生存率为95.2%(80%CI 83.9–98.7;95%CI 70.7–99.3)。
- 无90天围手术期死亡;发生4例4级治疗相关事件,但无4/5级放疗相关毒性效应。
- 照射癌栓患者Ki-67表达较未照射对照下降;所有有可用血浆的患者均检出肿瘤信息循环肿瘤DNA,且治疗后下降。
关键数值与推荐
- 主要终点为1年RFS,与预设历史单纯手术基准55.7%比较。
- 预设2期筛选标准已满足(P=.09),但作者强调结果仍属探索性。
- 入组患者中19例为透明细胞RCC,所有肿瘤均为3或4级,3例入组时已有转移。
临床怎么用
- 对于合并Mayo II–IV级下腔静脉癌栓的RCC患者,术前新辅助SABR可作为探索性治疗选择。
- 治疗决策需结合多学科评估,并充分告知证据仍来自非随机2期试验。
- SABR后行肾切除及癌栓切除围手术期安全性可接受,但仍需关注4级治疗相关事件。
局限性
- 为非随机单中心2期试验,样本量小(主要分析21例),结论属探索性。
- 主要终点采用预设历史对照基准比较,非同期随机对照。
- 随访时间范围跨度大,部分患者随访时间较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Renal cell carcinoma (RCC) with inferior vena cava (IVC) tumor thrombus is associated with substantial perioperative risk and frequent recurrence despite nephrectomy and thrombectomy. No established neoadjuvant local therapy exists for this high-risk population. OBJECTIVE: To evaluate the feasibility, safety, clinical outcomes, and exploratory biomarker effects of neoadjuvant stereotactic ablative radiotherapy (SABR) targeting IVC tumor thrombus before nephrectomy and thrombectomy. DESIGN, SETTING, AND PARTICIPANTS: This single-center prospective phase 2 nonrandomized clinical trial enrolled patients with newly diagnosed RCC and Mayo level II to IV IVC tumor thrombus eligible for neoadjuvant SABR and definitive surgery from July 2015 to January 2024. Data were analyzed from August 2025 to August 2026. INTERVENTION: Neoadjuvant SABR to the radiographically defined IVC tumor thrombus, delivered as 40 Gy in 5 fractions or 36 Gy in 3 fractions, followed by radical nephrectomy and IVC thrombectomy. MAIN OUTCOMES AND MEASURES: The primary end point was 1-year recurrence-free survival (RFS) compared with a prespecified historical surgery-alone benchmark of 55.7%. Secondary outcomes included 90-day perioperative morbidity and mortality, adverse events, pulmonary embolism, overall survival, and cancer-specific survival. Exploratory analyses included Ki-67 immunohistochemistry and tumor-informed circulating tumor DNA. RESULTS: Of 23 patients who received neoadjuvant SABR, 22 completed surgery, and 21 were included in the primary RFS analysis. Of 21 included patients, 12 (57%) were male, and the median (IQR) age was 62.5 (54.0-73.2) years. A total of 19 patients had clear-cell RCC; all tumors were grade 3 or 4, and 3 patients had metastatic disease at enrollment. At a median (range) follow-up of 108.6 (2.0-127.2) months, 1-year RFS was 71.4% (80% CI, 56.6-82.0; 95% CI, 47.2-86.0), meeting the prespecified phase 2 screening criterion based on comparison with the historical surgery-alone benchmark of 55.7% (P = .09). One-year overall survival was 95.2% (80% CI, 83.9-98.7; 95% CI, 70.7-99.3) and cancer-specific survival was 95.2% (80% CI, 83.9-98.7; 95% CI, 70.7-99.3). No 90-day perioperative mortality occurred; 4 grade 4 treatment-attributed events occurred, but no grade 4/5 radiation-attributed toxic effects occurred. Ki-67 expression was reduced in patients with irradiated tumor thrombus compared with nonirradiated controls. Tumor-informed circulating tumor DNA was detected in all patients with available plasma and declined after treatment. CONCLUSIONS AND RELEVANCE: In this nonrandomized clinical trial, neoadjuvant SABR before nephrectomy and IVC thrombectomy appeared feasible with an acceptable safety profile. RFS met the prespecified phase 2 screening criterion but remains exploratory and warrants further evaluation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02473536.
引用
- Hannan R, Lin L, Assadi R, et al. Neoadjuvant Stereotactic Ablative Radiotherapy Before Inferior Vena Cava Thrombectomy for Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2026. PMID: 42879162. doi:10.1001/jamaoncol.2026.4172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。